Miracor Medical Systems GmbH
Mariannengasse 14/14
A-1090
Vienna
Tel: t-43-0-1-236 657 612
Website: http://www.miracormedical.com/
Email: picso@miracormedical.com
26 articles about Miracor Medical Systems GmbH
-
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
8/23/2022
Miracor Medical SA has announced the approval of an Investigational Device Exemption from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion technology.
-
Miracor Medical starts 2nd randomized study, targeting expanded indications. 300 patients have been treated with PiCSO®
3/29/2022
Miracor Medical SA announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits of PiCSO® therapy as an adjunct to conventional primary percutaneous coronary intervention for patients presenting with inferior ST-Elevation Myocardial Infarction.
-
Miracor Medical Raises 24M€
9/2/2020
Miracor Medical SA has announced the closing of a 24M€ Series-E round of financing. The round was led by a new corporate strategic investor joined by co-investor Yonghua.
-
Miracor Medical’s PiCSO® System Receives CE Mark
6/23/2020
Miracor Medical SA has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients.
-
Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System
8/22/2019
Miracor Medical SA has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration for its PiCSO® Impulse System for treatment of STEMI patients.
-
Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU
7/25/2019
The first patient enrolled into this study was treated at Oxford Heart Center, Oxford, UK by Professor Adrian Banning, the principal investigator of the study.
-
Miracor Medical closes final tranche of Series-D, bringing the round to €30M
9/4/2018
Funds will be used to support clinical and prepare commercial activities.
-
PiCSO therapy reduces infarct size in STEMI patients.
5/24/2018
Miracor Medical announces new publication at EuroPCR.
-
Miracor Medical Raises €25M
1/4/2018
The new capital will be used to further develop and commercialize the PiCSO Impulse System. -
Miracor Medical Systems GmbH Announces Positive Interim Clinical Data With Novel Picso Impulse System For AMI Patients
6/6/2017
-
Miracor Medical Systems GmbH Receives Additional Funding In Series-C Closing To Expand Clinical And Commercial Activities With The PiCSO Impulse System
10/25/2016
-
Antonio Colombo, MD Appointed Member Of The Scientific Advisory Council Of Miracor Medical Systems GmbH
12/10/2015
-
Miracor Medical Systems GmbH’s PiCSO Impulse System Highlighted As Novel Therapy For Cardioprotected PCI At TCT 2015 In San Francisco
10/29/2015
-
Miracor Medical Systems GmbH Launches PiCSO Impulse System in Asia
9/21/2015
-
Miracor Medical Systems GmbH Appoints International Scientific Advisory Council
6/30/2015
-
Miracor Medical Systems GmbH Expands in the U.K.; Opens Up New Sales Office
4/2/2015
-
Miracor Medical Systems GmbH Increases Clinical And Commercial Activities In The UK
3/31/2015
-
Miracor Medical Systems GmbH Receives Additional Funding To Accelerate Clinical Validation And Commercialization Of Its PICSO® Impulse System
1/8/2015
-
Miracor Medical Systems GmbH To Release Latest Clinical Data About Its PICSO Impulse System At “Europcr 2014” Next Week
5/13/2014
-
Miracor Medical Systems GmbH Successfully Completes Enrollment of 30 Patients in a Safety and Feasibility Study Using its PICSO® System to Treat Severe Heart Attack Patients Post-Primary PCI
11/11/2013